Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Comparison 2020 to 2021

<< Previous

Bullboard Posts

Next >>

Post by Golddetectoron Feb 28, 2022 9:37pm

193 Views

Post# 34469721

Comparison 2020 to 2021

The nr shows a lot of progress compared with end 2020 we have Reduvo din anytime now we have QIXLEEF reborn phase 1 to be completed and phase 2 to start. And ard003 ready to start trials and yet sp is half and mc is reduced. After spending 30M last year alone to push this development. Market cap now is sitting at 35M. Yes there are delays but looking at the big picture the sp looks stupid considering all trials are so far successful.

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle